Aug 16 |
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
|
Aug 1 |
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
|
Aug 1 |
Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease
|
Jul 22 |
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien
|
Jul 9 |
RedHill terminates license agreement with Cosmo Technologies
|
Jul 9 |
RedHill Biopharma Terminates License Agreement for Aemcolo®
|
May 6 |
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
|
Apr 24 |
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
|
Apr 8 |
RedHill GAAP EPS of $0.01, revenue of $6.53M
|
Apr 8 |
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
|